220 related articles for article (PubMed ID: 24816187)
1. Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.
Moisan F; Francisco EB; Brozovic A; Duran GE; Wang YC; Chaturvedi S; Seetharam S; Snyder LA; Doshi P; Sikic BI
Mol Oncol; 2014 Oct; 8(7):1231-9. PubMed ID: 24816187
[TBL] [Abstract][Full Text] [Related]
2. The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells.
Brozovic A; Duran GE; Wang YC; Francisco EB; Sikic BI
Mol Oncol; 2015 Oct; 9(8):1678-93. PubMed ID: 26025631
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Ovarian Cancer Cells
Kuittinen T; Rovio P; Luukkaala T; Laurila M; Grénman S; Kallioniemi A; Mäenpää J
Anticancer Res; 2020 Jun; 40(6):3129-3138. PubMed ID: 32487607
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy for ovarian cancer: an evidence-based approach.
Geisler JP; Manahan KJ; Wiemann MC
Minerva Ginecol; 2004 Dec; 56(6):539-45. PubMed ID: 15729206
[TBL] [Abstract][Full Text] [Related]
5. Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells.
Stamelos VA; Robinson E; Redman CW; Richardson A
Gynecol Oncol; 2013 Feb; 128(2):377-82. PubMed ID: 23168176
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy induces macrophage chemoattractant protein-1 production in ovarian cancer.
Geller MA; Bui-Nguyen TM; Rogers LM; Ramakrishnan S
Int J Gynecol Cancer; 2010 Aug; 20(6):918-25. PubMed ID: 20683396
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin.
Scalici JM; Harrer C; Allen A; Jazaeri A; Atkins KA; McLachlan KR; Slack-Davis JK
Gynecol Oncol; 2014 Feb; 132(2):455-61. PubMed ID: 24378876
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab, Carboplatin and Paclitaxel Combination Treatment in Advanced Stage Ovarian Cancer: The First Experience in Thammasat University Hospital, Thailand: A Case Report.
Suwannarurk K; Thaweekul Y; Mairaing K; Poomtavorn Y; Tangtiang K; Piyawang W; Bhamarapravatana K
J Med Assoc Thai; 2015 Apr; 98 Suppl 3():S121-5. PubMed ID: 26387399
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
[TBL] [Abstract][Full Text] [Related]
10. Nilotinib in combination with carboplatin and paclitaxel is a candidate for ovarian cancer treatment.
Weigel MT; Rath K; Alkatout I; Wenners AS; Schem C; Maass N; Jonat W; Mundhenke C
Oncology; 2014; 87(4):232-45. PubMed ID: 25116401
[TBL] [Abstract][Full Text] [Related]
11. The effect of age on first-line chemotherapy for epithelial ovarian cancer and primary peritoneal carcinoma.
Larbi E; Madhuri K; Essapen S; Butler-Manuel S; Tailor A; Michael A
Clin Oncol (R Coll Radiol); 2013 Jan; 25(1):75. PubMed ID: 23146339
[No Abstract] [Full Text] [Related]
12. Combination chemotherapy of intraperitoneal carboplatin and intravenous paclitaxel in suboptimally debulked epithelial ovarian cancer.
Nagao S; Fujiwara K; Ohishi R; Nakanishi Y; Iwasa N; Shimizu M; Goto T; Shimoya K
Int J Gynecol Cancer; 2008; 18(6):1210-4. PubMed ID: 18284454
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.
Takahashi R; Mabuchi S; Kawano M; Sasano T; Matsumoto Y; Kuroda H; Kozasa K; Hashimoto K; Sawada K; Kimura T
PLoS One; 2016; 11(3):e0151050. PubMed ID: 26986199
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel and carboplatin for advanced breast cancer.
Perez EA; Hartmann LC
Semin Oncol; 1996 Oct; 23(5 Suppl 11):41-5. PubMed ID: 8893899
[TBL] [Abstract][Full Text] [Related]
15. Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.
Glaser G; Weroha SJ; Becker MA; Hou X; Enderica-Gonzalez S; Harrington SC; Haluska P
PLoS One; 2015; 10(5):e0126867. PubMed ID: 25962155
[TBL] [Abstract][Full Text] [Related]
16. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
17. Case of pure ovarian squamous cell carcinoma resistant to combination chemotherapy with paclitaxel and carboplatin but responsive to monotherapy with weekly irinotecan.
Nakamura Y; Kamei T; Shinagawa M; Sakamoto Y; Miwa I
J Obstet Gynaecol Res; 2015 May; 41(5):809-12. PubMed ID: 25511544
[TBL] [Abstract][Full Text] [Related]
18. Optoacoustic imaging identifies ovarian cancer using a microenvironment targeted theranostic wormhole mesoporous silica nanoparticle.
Samykutty A; Grizzle WE; Fouts BL; McNally MW; Chuong P; Thomas A; Chiba A; Otali D; Woloszynska A; Said N; Frederick PJ; Jasinski J; Liu J; McNally LR
Biomaterials; 2018 Nov; 182():114-126. PubMed ID: 30118979
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
[TBL] [Abstract][Full Text] [Related]
20. [Carboplatin in cancer of the ovary].
Pujade-Lauraine E; Guastalla JP; Vincent P
Bull Cancer; 2000 Aug; 87 Spec No():40-7. PubMed ID: 11082722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]